August 16, 2018
Astellas Pharma’s acute myeloid leukemia (AML) treatment gilteritinib and Pfizer’s next-generation ALK inhibitor lorlatinib will come up for review by a key health ministry panel on August 29, and its nod, if given, could open the way for their official...read more